The role of interferon regulatory factors in the interferon system and cell growth control

Biochimie

Volumn 80, Issue 8-9, 1998, Pages 641-650

  Harada, Hisashi ^a   Taniguchi, Tadatsugu ^b   Tanaka, Nobuyuki ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cell growth control; Interferon regulatory factor; Interferon response; Transcription

Indexed keywords

BETA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; TRANSCRIPTION FACTOR;

CARCINOGENESIS; CELL GROWTH; CELL TRANSFORMATION; CELL TYPE; CONTROLLED STUDY; DNA SYNTHESIS; GENE ACTIVATION; GENE DELETION; GENE INDUCTION; GENE TARGETING; GENETIC REGULATION; HOST RESISTANCE; HUMAN; HUMAN CELL; INFECTION; LEUKEMIA; MYELODYSPLASTIC SYNDROME; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION REGULATION;

EID: 0032130972     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(99)80017-0     Document Type: Article

References (72)

1. [1] Pestka S., Langer A.J., Zoon K., Samuel C., Interferons and their actions, Annu. Rev. Biochem. 56 (1987) 727-777.
2. [2] De Maeyer E., De Maeyer-Guignard J., Interferons and Other Regulatory Cytokines, John Wiley & Sons, New York, 1988.
3. [3] Vilcek J., Interferons, in: Sporn M.A., Roberts B. (Eds.), Peptide Growth Factors and Their Receptors II, Springer-Verlag, Berlin, (1990) 3 p.
4. [4] Sen G.C., Ranshoff R.M., Interferon-induced antiviral actions and their regulation, Adv. Virus Res. 42 (1993) 57-102.
5. [5] Fujita T., Sakakibara J., Sudo Y., Miyamoto M., Kimura Y., Taniguchi T., Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN-β gene regulatory elements, EMBO J. 7 (1988) 3397-3405.
6. [6] Miyamoto M., Fujita T., Kimura Y., Maruyama M., Harada H., Sudo H., Miyata T., Taniguchi T., Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-β gene regulatory elements, Cell 54 (1988) 903-913.
7. [7] Harada H., Fujita T., Miyamoto M., Kimura Y., Maruyama M., Furia A., Miyata T., Taniguchi T., Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes, Cell 58 (1989) 729-739.
8. [8] Au W.C., Moore P.A., Lowther W., Juang Y.T., Pitha P.M., Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes, Proc. Natl. Acad. Sci. USA 92 (1995) 11657-11661.
9. [9] Matsuyama T., Grossman A., Mittrucker H.W., Siderovski D.P., Kiefer F., Kawakami T., Richardson C.D., Taniguchi T., Yoshinaga S.K., Mak T.W., Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE), Nucleic Acids Res. 23 (1995) 2127-2136.
10. [10] Eisenbeis C.F., Singh H., Storb U., Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator, Genes Dev. 9 (1995) 1377-1387.
11. [11] Yamagata T., Nishida J., Tanaka T., Sakai R., Mitani K., Yoshida M., Taniguchi T., Yazaki Y., Hirai H., A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes, Mol. Cell. Biol. 16 (1996) 1283-1294.
12. [12] Zhang L., Pagano J.S., IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency, Mol. Cell. Biol. 17 (1997) 5748-5757.
13. [13] Veals S.A., Schindler C., Leonard D., Fu X.Y., Aebersold R., Darnell J.E. Jr., Levy D.E., Subunit of alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins, Mol. Cell. Biol. 12 (1992) 3315-3324.
14. [14] Driggers P.H., Ennist D.L., Gleason S.L., Mak W., Marks M.S., Levi B., Flanagan J.R., Appella E., Ozato K., An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes, Proc. Natl. Acad. Sci. USA 87 (1990) 3743-3747.
15. [15] Moore P.S., Boshoff C., Weiss R.A., Chang Y., Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV, Science 274 (1996) 1739-1744.
16. [16] Macdonald N.J., Kuhl D., Maguire D., Naf D., Gallant P., Goswamy A., Hug H., Bueler H., Chaturvedi M., De LaFuente J., Ruffner H., Meyer F., Weissmann C., Different pathways mediate virus inducibility of the human IFN-α1 and IFN-β genes, Cell 60 (1990) 767-779.
17. [17] Taniguchi T., Harada H., Lamphier M.S., Regulation of the interferon system and cell growth by the IRF transcription factors, J. Cancer Res. Clin. Oncol. 121 (1995) 516-520.
18. [18] Thanos D., Maniatis T., Virus induction of human IFNβ gene expression requires the assembly of an enhanceosome, Cell 83 (1995) 1091-1100.
19. [19] Tanaka N., Kawakami T., Taniguchi T., Recognition DNA sequence of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system, Mol. Cell. Biol. 13 (1993) 4531-4538.
20. [20] Uegaki K., Shirakawa M., Harada H., Taniguchi T., Kyogoku Y., Secondary structure and folding topology of the DNA binding domain of interferon regulatory factor 2, as revealed by NMR spectroscopy, FEBS Lett. 359 (1995) 184-188.
21. [21] Escalante C.R., Yie J., Thanos D., Aggarwal A.K., Structure of IRF-1 with bound DNA reveals determinants of interferon regulation, Nature 391 (1998) 103-106.
22. [22] Fujita T., Kimura Y., Miyamoto M., Barsoumian E.L., Taniguchi T., Induction of endogenous IFN-α and IFNβ genes by a regulatory transcription factor, IRF-1, Nature 337 (1989) 270-272.
23. [23] Harada H., Willison K., Sakakibara J., Miyamoto M., Fujita T., Taniguchi T., Absence of type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated, Cell 63 (1990) 303-312.
24. [24] Matsuyama T., Kimura T., Kitagawa M., Pfeffer K., Kawakami T., Watanabe N., Kondig T.M., Amakawa R., Kishihara K., Wakeham A., Potter J., Furlonger C.L., Narendran A., Suzuki H., Ohashi P.S., Paige C.J., Taniguchi T., Mak T.W., Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development, Cell 75 (1993) 83-97.
25. [25] Reis L.F.L., Ruffner H., Stark G., Aguet M., Weissmann C., Mice devoid of IRF-1 show normal expression of type I IFN genes, EMBO J. 13 (1994) 4798-4806.
26. [26] Kimura T., Nakayama K., Penninger J., Kitagawa M., Harada H., Matsuyama T., Tanaka N., Kamijo R., Vilcek J., Mak T.W., Taniguchi T., Involvement of the IRF-1 transcription factor in antiviral responses to interferons, Science 264 (1994) 1921-1924.
27. [27] Briken V., Ruffner H., Schultz U., Schwarz A., Reis L.F.L., Strehlow I., Decker T., Staeheli P., Interferon regulatory factor 1 is required for mouse Gbp gene activation by gamma interferon, Mol. Cell. Biol. 15 (1995) 975-982.
28. [28] Kamijo R., Harada H., Matsuyama T., Bosland M., Gerecitano J., Shapiro D., Le J., Koh S.I., Kimura T., Green S.J., Mak T.W., Taniguchi T., Vilcek J., Requirement of transcription factor IRF-1 in NO synthase induction in macrophages, Science 263 (1994) 1612-1615.
29. [29] Bluyssen H.A.R., Durbin J.F., Levy D.E., ISGF3γ p48, a specificity switch for IFN activated transcriptional factors, Cytokine Growth Factor Rev. 7 (1996) 11-17.
30. [30] Darnell J.E. Jr., Kerr I.M., Stark G.R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular proteins, Science 264 (1994) 1415-1421.
31. [31] Kimura T., Kadokawa Y., Harada H., Matsumoto M., Sato M., Kashiwazaki Y., Tarutani M., Tan R.S.P., Takasugi T., Matsuyama T., Mak T.W., Noguchi S., Taniguchi T., Essential and non-redundant roles of p48 (ISGF3γ) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies, Genes Cells 1 (1996) 115-124.
32. [32] Pine R., Canova A., Schindler C., Tyrosine phosphorylated p91 binds to a single element in the ISGF2/IRF-1 promoter to mediate induction by IFNα and IFNγ, and is likely to autoregulate the p91 gene, EMBO J. 13 (1994) 158-167.
33. [33] Bluyssen H.A., Muzaffar R., Vlieststra R.J., Van DerMade A.C., Leung S., Stark G.R., Kerr I.M., Trapman J., Levy D.E., Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses, Proc. Natl. Acad. Sci. USA 92 (1995) 5645-5649.
34. [34] Kawakami T., Matsumoto M., Sato M., Harada H., Taniguchi T., Kitagawa M., Possible involvement of the transcription factor ISGF3γ in virus-induced expression of the IFN-β gene, FEBS Lett. 358 (1995) 225-229.
35. [35] Harada H., Matsumoto M., Sato M., Kashiwazaki Y., Kimura T., Kitagawa M., Yokochi T., Tan R.S.P., Takasugi T., Kadokawa Y., Schindler C., Schreiber R.D., Noguch I.S., Taniguch I.T., Regulation of IFN-α/β genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN-α/β, Genes Cells 1 (1996) 995-1005.
36. [36] Muller U., Steinhoff U., Reis, L.F.L., Hemmi S., Pavlovic J., Zinkernagel R.M., Aguet M., Functional role of type I and type II interferons in antiviral defense, Science 264 (1994) 1918-1921.
37. [37] Meraz, M.A., White, J.M., Sheehan K.C., Bach E.A., Rodig S.J., Dighe A.S., Kaplan D.H., Riley J.K., Greenlund A.C., Campbell D., Carver-Moore K., Dubois R.N., Clark R., Aguel M., Schreiber R.D., Targeted disruption of the Statl gene in mice reveals unexpected physiologic specificity in the Jak-Stat signaling pathway, Cell 84 (1996) 431-422.
38. [38] Yoneyama M., Suhara W., Fukuhara Y., Sato M., Ozato K., Fujita T., Autocrine amplification of type I interferon gene expression mediated by interferon stimulated gene factor 3 (ISGF3), J. Biochem. 120 (1996) 160-169.
39. [39] Yoneyama M., Suhara W., Fukuhara Y., Fukuda M., Nishida E., Fujita T., Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300, EMBO J. 17 (1998) 1087-1095.
40. [40] Weaver B.K., Kumar K.P., Reich N.C., Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1, Mol. Cell. Biol. 18 (1998) 1359-1368.
41. [41] Yamada G., Ogawa M., Akagi K., Miyamoto H., Nakano N., Itoh S., Miyazaki J., Nishikawa S., Yamamura K., Taniguchi T., Specific depletion of the B-cell population induced by aberrant expression of human interferon regulatory factor 1 gene in transgenic mice, Proc. Natl. Acad. Sci. USA 88 (1990) 532-536.
42. [42] Kirchhoff S., Schaper F., Hauser H., Interferon regulatory factor 1 (IRF-1) mediates cell growth inhibition by transactivation of downstream target genes, Nucleic Acids Res. 21 (1993) 2889
43. [43] Harada H., Kitagawa M., Tanaka N., Yamamoto H., Harada K., Ishihara M., Taniguchi T., Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2, Science 259 (1993) 971-974.
44. [44] Tanaka N., Ishihara M., Taniguchi T., Suppression of c-myc or fosB-induced cell transformation by the transcription factor IRF-1, Cancer Lett. 83 (1994) 191-196.
45. [45] Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A.J.R., Bytel J.S., Bradley A., Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours, Nature 356 (1992) 215-221.
46. [46] Tanaka N., Ishihara M., Kitagawa M., Harada H., Kimura T., Matsuyama T., Lamphier M.S., Aizawa S., Mak T.W., Taniguchi T., Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1, Cell 77 (1994) 829-839.
47. [47] White E., Life, death, and the pursuit of apoptosis, Genes Dev. 10 (1996) 1-15.
48. [48] Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T., p53 is required for radiation-induced apoptosis in mouse thymocytes, Nature 362 (1993) 847-849.
49. [49] Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., Wyllie A.H., Thymocyte apoptosis induced by p53-dependent and independent pathways, Nature 362 (1993) 852.
50. [50] Strasser A., Harris A.W., Jacks T., Cory S., DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2, Cell 79 (1994) 329-339.
51. [51] Tamura T., Ishihara M., Lamphier M.S., Tanaka N., Oishi I., Aizawa S., Matsuyama T., Mak T.W., Taki S., Taniguchi T., An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes, Nature 376 (1995) 596-599.
52. [52] Tan R.S.P., Taniguchi T., Harada H., Identification of the lysyl oxidase gene as a target of the antioncogenic transcription factor, IRF-1 and its possible role in tumor suppression, Cancer Res. 56 (1996) 2417-2421.
53. [53] Tanaka N., Ishihara M., Lamphier M.S., Nozawa H., Matsuyama T., Mak T.W., Aizawa S., Tokino T., Oren M., Taniguchi T., Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage, Nature 382 (1996) 816-818.
54. [54] Vogelstein B., Kinzler K.W., p53 function and dysfunction, Cell 70 (1992) 523-526.
55. [55] Kirchhoff S., Koromilas A.E., Schaper F., Grashoff M., Sonenberg N., Hauser H., IRF-1 induced cell growth inhibition and interferon induction requires the activity of the protein kinase PKR, Oncogene 11 (1995) 439-445.
56. [56] Nguyen H., Lin R., Hiscott J., Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins, Oncogene 15 (1997) 1425-1435.
57. [57] Beretta L., Gabbay M., Berger R., Hanash S.M., Sonenberg N., Expression of the protein kinase PKR is modified by IRF-1 and is reduced in 5q-associated leukemias, Oncogene 12 (1996) 1593-1596.
58. [58] Harada H., Takahashi E., Itoh S., Harada K., Hori T., Taniguchi T., Structure and regulation of the human interferon regulatory factor-I(IRF-1) and IRF-2 genes: implications for a gene network in the interferon system, Mol. Cell. Biol. 14 (1994) 1500-1509.
59. [59] Willman C.L., Sever C.E., Pallavicini M.G., Harada H., Tanaka N., Slovak M.L., Yamamoto H., Harada K., Meeker T.C., List A.F., Taniguchi T., Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia, Science 259 (1993) 968-971.
60. [60] LeBeau M.M., Deletion of chromosome 5 in malignant myeloid disorders, in: Witte O.W. (Ed.), Oncogene in the development of Leukemia, Cold Spring Harbor Laboratory Press, New York, 1992, 143 p.
61. [61] Boultwood J., Fidler C., Lewis S., Maccarthy A., Sheridan H., Kelly S., Oscier D., Buckle V.J., Wainscoat J.S., Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q-chromosome in some patients with the 5q-syndrome, Blood 82 (1993) 2611-2616.
62. [62] Harada H., Kondo T., Ogawa S., Tamura T., Kitagawa M., Tanaka N., Lamphier M.S., Hirai H., Taniguchi T., Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation, Oncogene 9 (1994) 3313-3320.
63. [63] Kondo T., Minamino N., Nagamura-Inoue T., Matsumoto M., Taniguchi T., Tanaka N., Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity, Oncogene 15 (1997) 1275-1281.
64. [64] Yamamoto H., Lamphier M.S., Fujita T., Taniguchi T., Harada H., The oncogenic transcription factor IRF-2 possesses a transcriptional repression and a latent activation domain, Oncogene 9 (1994) 1423-1428.
65. [65] Ramsey-Ewing A., van Wijnen A.J., Stein G.S., Stein J.L., Delineation of a human histone H4 cell cycle element in vivo: the master switch for H4 gene transcription, Proc. Natl. Acad. Sci. USA 91 (1994) 4475-4479.
66. [66] Vaughan P.S., Aziz F., van Wijnen A.J., Wu S., Harada H., Taniguchi T., Soprano K.J., Stein G.S., Stein J.L., Activation of a cell-cycle regulated histone gene by the oncogenic transcription factor IRF-2, Nature 377 (1995) 362-365.
67. [67] Nelson N., Kanno Y., Hong C., Contursi C., Fujita T., Fowlkes B.J., O' Connell E., Hu-Li J., Paul W.E., Jankovic D., Sher A.F., Coligan J.E., Thornton A., Appella E., Yang Y., Ozato K., Expression of interferon regulatory factor family proteins in lymphocytes: induction of Stat1 and ICSBP expression by T cell activation, J. Immunol. 156 (1996) 3711-3720.
68. [68] Bovolenta C., Driggers P.H., Marks M.S., Medin J.A., Poltis A.D., Vogel S.N., Levy D.E., Sakaguchi K., Appella E., Coligan J.E., Ozato K., Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family, Proc. Natl. Acad. Sci. USA 91 (1994) 5046-5050.
69. [69] Holtschke T., Lohler J., Kanno Y., Fehr T., Giese N., Rosenbauer F., Lou J., Knobeloch K.P., Gabriele L., Waring J.F., Bachmann M.F., Zinkernagel R.M., Morse H.C., Ozato K., Horak I., Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene, Cell 87 (1996) 307-317.
70. [70] Mittrucker H.W., Matsuyama T., Grossman A., Kundig T.M., Potter J., Shahinian A., Wakeham A., Patterson B., Ohashi P.S., Mak T.W., Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function, Science 275 (1997) 543.
71. [71] Iida S., Rao P.H., Butler M., Corradini P., Boccadoro M., Klein B., Chaganti R.S.K., Dalla-Favera R., Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma, Nature Genet. 17 (1997) 226-230.
72. [72] Gao S.J., Boshoff C., Jayachandra S., Weiss R.A., Chang Y., Moore P.S., KHSV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway, Oncogene 15 (1997) 1979-1985.